[New diagnostic and therapeutic aspects of lymphogranulomatosis]. 1976

W Helbig

The prognosis of lymphogranulomatosis has improved by the considerably improved diagnostics as well as the modern radiological and polychemo-therapeutical methods. Today the average survival time is between 4 and 5 years. But survival times up to 15 years and more are described. Apart from the early diagnosis, into which according to the opinion of many internal specialists the otorhinolaryngologists must be included more than it was hitherto the case, nowadays the modern radiotherapy with explorative laparotomy and splenectomy and the perhaps following combination chemotherapy might bring a further improvement. Growing age, histological types with a small number of lymphocytes, too late diagnosis and deficient control decrease, however, signigicantly the chances of surviving. Certainly, in future more modern methods of chemotherapy must be used. The same applies to the treatment of the developing immunoinsufficiency and the eventual further performance of the cytostatic treatment in the sense of a maintenance therapy. From the modern point of view the way taken might lead to still higher survival times. In as far immunotherapy will be of greater importance already in the next years is not yet to be decided at present.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011867 Radioisotope Teletherapy A type of high-energy radiotherapy using a beam of gamma-radiation produced by a radioisotope source encapsulated within a teletherapy unit. Teleradioisotope Therapy,Teletherapy, Radioisotope,Therapy, Teleradioisotope
D003037 Cobalt Radioisotopes Unstable isotopes of cobalt that decay or disintegrate emitting radiation. Co atoms with atomic weights of 54-64, except 59, are radioactive cobalt isotopes. Radioisotopes, Cobalt
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

W Helbig
June 1980, Ugeskrift for laeger,
W Helbig
November 1950, La Presse medicale,
W Helbig
January 1979, Acta medica Austriaca. Supplement,
W Helbig
September 1997, Schweizerische medizinische Wochenschrift,
W Helbig
January 1998, Kidney & blood pressure research,
W Helbig
October 1993, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
W Helbig
April 1968, Terapevticheskii arkhiv,
Copied contents to your clipboard!